GlassScriptPhysician profile
Kaman Lindgren
NPI 1811522766
$3,322.98
in general payments reported to CMS, 2019-2025
17 companies · $1,209 in 2025
The $1,209 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $748 · 2024: $1,251 · 2025: $1,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.80 |
| Education | $161.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $976.28 | 2023-2025 | Carvykti, Rybrevant, Erleada |
| Glaxosmithkline, LLC. | $347.07 | 2023-2024 | Zejula, Ojjaara, Jemperli |
| Abbvie INC. | $289.36 | 2024-2025 | |
| Pfizer INC. | $235.76 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $229.20 | 2023 | Onureg, Reblozyl |
| Merck Sharp & Dohme LLC | $189.39 | 2023-2024 | Lynparza, Keytruda |
| Adaptive Biotechnologies Corporation | $162.88 | 2025 | Clonoseq |
| Astellas Pharma US INC | $125.00 | 2024 | Xospata |
| Agios Pharmaceuticals, INC. | $121.72 | 2024 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $120.62 | 2025 | Givlaari |
| Amgen INC. | $119.67 | 2024 | Evenity |
| Seagen INC. | $115.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.56 | 2025 | Fruzaqla |
| Stemline Therapeutics INC. | $83.33 | 2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $81.29 | 2025 | Libtayo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $19.71 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $17.94 | 2025 | Enhertu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaman Lindgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.